Next-generation BTK inhibitors and their value in CLL
Current and potential PI3K and BTK inhibitors for CLL
Overview of RESONATE-2 clinical trial of ibrutinib in CLL
John Gribben et al.
How can we overcome ibrutinib resistance?
How to treat Richter’s transformation